Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
07 2019
Historique:
received: 26 10 2018
revised: 14 02 2019
accepted: 07 03 2019
pubmed: 6 5 2019
medline: 20 6 2020
entrez: 6 5 2019
Statut: ppublish

Résumé

We conducted a multilaboratory assessment to determine the suitability of a new commercially available reference material with 40 cancer variants in a background of wild-type DNA at four different variant allele frequencies (VAFs): 2%, 0.50%, 0.125%, and 0%. The variants include single nucleotides, insertions, deletions, and two structural variations selected for their clinical importance and to challenge the performance of next-generation sequencing (NGS) methods. Fragmented DNA was formulated to simulate the size distribution of circulating wild-type and tumor DNA in a synthetic plasma matrix. DNA was extracted from these samples and characterized with different methods and multiple laboratories. The various extraction methods had differences in yield, perhaps because of differences in chemistry. Digital PCR assays were used to measure VAFs to compare results from different NGS methods. Comparable VAFs were observed across the different NGS methods. This multilaboratory assessment demonstrates that the new reference material is an appropriate tool to determine the analytical parameters of different measurement methods and to ensure their quality assurance.

Identifiants

pubmed: 31055023
pii: S1525-1578(18)30479-3
doi: 10.1016/j.jmoldx.2019.03.006
pmc: PMC6626992
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Circulating Tumor DNA 0
DNA, Neoplasm 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

658-676

Subventions

Organisme : NIGMS NIH HHS
ID : R43 GM128522
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA181009
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208599
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA229037
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA210170
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Références

Clin Cancer Res. 2016 Feb 15;22(4):915-22
pubmed: 26459174
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1317-25
pubmed: 25646427
Anal Biochem. 2006 Nov 15;358(2):247-56
pubmed: 16942746
BMC Genomics. 2015 Aug 07;16:589
pubmed: 26248467
JAMA. 2017 Oct 3;318(13):1272-1274
pubmed: 28973237
Cell. 2017 Feb 9;168(4):571-574
pubmed: 28187279
Nucleic Acids Res. 2016 Jun 20;44(11):e105
pubmed: 27060140
Nat Rev Genet. 2018 May;19(5):269-285
pubmed: 29576615
Mol Oncol. 2019 Feb;13(2):392-402
pubmed: 30516338
Bioinformatics. 2015 Nov 1;31(21):3476-82
pubmed: 26139637
BMC Genomics. 2012 Jul 24;13:341
pubmed: 22827831
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Sci Rep. 2018 May 9;8(1):7375
pubmed: 29743667
Anal Bioanal Chem. 2014 Oct;406(26):6499-512
pubmed: 24853859
Anal Biochem. 2014 Apr 15;451:18-24
pubmed: 24495734
Transl Lung Cancer Res. 2016 Dec;5(6):665-672
pubmed: 28149760
Trends Genet. 2016 Jun;32(6):360-371
pubmed: 27129983
Front Mol Biosci. 2015 Apr 22;2:13
pubmed: 25988180
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Nucleic Acids Res. 2012 Jan;40(1):e3
pubmed: 22021376
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Cancer Genet. 2018 Dec;228-229:21-27
pubmed: 30553469
Clin Biochem Rev. 2007 Nov;28(4):139-47
pubmed: 18392124
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14508-13
pubmed: 22853953
J Mol Diagn. 2017 Jan;19(1):162-168
pubmed: 27865784
Nat Biotechnol. 2019 May;37(5):555-560
pubmed: 30858580
PLoS One. 2017 Apr 27;12(4):e0176241
pubmed: 28448587
Biotechniques. 2018 Feb 1;64(2):59-68
pubmed: 29571283
Gut. 2017 Sep;66(9):1677-1687
pubmed: 27432539
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3178-9
pubmed: 25733911
Nat Protoc. 2017 Apr;12(4):664-682
pubmed: 28253235
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Ther Clin Risk Manag. 2017 Oct 11;13:1363-1374
pubmed: 29066904
Mol Cancer Res. 2016 Oct;14(10):898-908
pubmed: 27422709
Clin Cancer Res. 2018 Jun 15;24(12):2963-2974
pubmed: 29301828
Genome Res. 2013 May;23(5):843-54
pubmed: 23382536
J Mol Diagn. 2018 Sep;20(5):583-590
pubmed: 29959024

Auteurs

Hua-Jun He (HJ)

Material Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland.

Erica V Stein (EV)

Material Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland.

Yves Konigshofer (Y)

SeraCare Life Sciences, Inc., Milford, Massachusetts.

Thomas Forbes (T)

Frederick National Laboratory for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Inc., Frederick, Maryland.

Farol L Tomson (FL)

SeraCare Life Sciences, Inc., Milford, Massachusetts.

Russell Garlick (R)

SeraCare Life Sciences, Inc., Milford, Massachusetts.

Emiko Yamada (E)

Boston University School of Medicine, Boston, Massachusetts.

Tony Godfrey (T)

Boston University School of Medicine, Boston, Massachusetts.

Toshiya Abe (T)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Koji Tamura (K)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Michael Borges (M)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Michael Goggins (M)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Sandra Elmore (S)

University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Margaret L Gulley (ML)

University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Jessica L Larson (JL)

Asuragen, Inc., Austin, Texas.

Lando Ringel (L)

Asuragen, Inc., Austin, Texas.

Brian C Haynes (BC)

Asuragen, Inc., Austin, Texas.

Chris Karlovich (C)

Frederick National Laboratory for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Inc., Frederick, Maryland.

P Mickey Williams (PM)

Frederick National Laboratory for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Inc., Frederick, Maryland.

Aaron Garnett (A)

Archer Diagnostics, Inc., Boulder, Colorado.

Anders Ståhlberg (A)

Department of Pathology and Genetics, Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Sweden.

Stefan Filges (S)

Department of Pathology and Genetics, Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Lynn Sorbara (L)

Early Detection Research Network, National Cancer Institute, Bethesda, Maryland.

Mathew R Young (MR)

Early Detection Research Network, National Cancer Institute, Bethesda, Maryland.

Sudhir Srivastava (S)

Early Detection Research Network, National Cancer Institute, Bethesda, Maryland.

Kenneth D Cole (KD)

Material Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland. Electronic address: kenneth.cole@nist.gov.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH